Introduction
Though effective control programmes have been implemented, TB continues to be a major lethal infectious disease worldwide, with an estimated of 10 million new cases and 1.45 million deaths in 2018 [
1]. This situation is complicated further by the emergence of drug-resistant strains, dramatically limiting the treatment options. Hence, improved treatment regimens and new drugs are urgently needed to be developed. Based on the latest evidence about the balance of effectiveness to safety, the new multidrug resistant tuberculosis (MDR-TB) treatment guidelines were released in 2018 by World Health Organization (WHO) with medicines regrouped into three categories [
2].
China has the second greatest number of MDR-TB cases in the world
1. According to the Fifth National TB Epidemiological Survey, the prevalence of active and smear positive pulmonary TB in western China was greater than that in the middle and eastern regions, which was also higher than the rate of the whole country [
3]. Due to the remote mountainous areas and ethnic minorities, it is more difficult to control TB in southwest China. Besides, there is a lack of resistance data on the drugs in the MDR-TB treatment regimen recommended by WHO.
The objective of this study was to explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), and linezolid (LZD) from group A, clofazimine (CFZ) from group B and delamanid (DLM) from group C against MDR-TB isolates from drug resistance survey of southwest China on the basis of minimum inhibitory concentrations (MIC), and to illustrate the genetic characteristics of MDR-TB isolates with acquired drug resistance.
Results
Drug susceptibility profiles of MDR-TB strains
MDR was observed in 88 (26.0%; 88/339) isolates with 59 (67.0%; 59/88) resistant to SM, 28 (31.8%; 28/88) resistant to EMB, 6 (6.8%; 6/88) resistant to CAP, 11 (12.5%; 11/88) resistant to KAN, and 35 (39.8%; 35/88) resistant to OFX. In addition, 9 isolates (10.2%; 9/88) were identified as XDR strains.
The results of MICs for MDR-TB isolates against six antibiotics were shown in Table
1. LFX had the highest resistance rate (50.0%; 44/88), followed by MFX (38.6%; 34/88). The resistance rate to LZD, CFZ, and DLM was 4.5% (4/88), 3.4% (3/88), and 4.5% (4/88), respectively, and the lowest resistance rate was observed in BDQ (2.3%; 2/88). In addition, out of the 44 LFX-resistant isolates, 33 (75%) were resistant to MFX, and 2 (66.7%) out of the 3 CFZ-resistant isolates were resistant to BDQ.
Mutations conferring antibiotics resistance
Among the 45 isolates resistant to FQs (44 isolates resistant to LFX, 34 isolates resistant to MFX, and 33 isolates cross resistant to LFX and MFX), the most prevalent resistance mutation of
gyrA was the substitution in codon 94 (34/45, 75.6%), resulting in the amino acid substitution of Asp for 13 (13/45, 28.9%) Gly, 11 (11/45, 24.4%) Tyr, 6 (6/45, 13.3%) Ala, and 4 (4/45, 8.9%) Asn. In addition, the second most common substitution occurred in codon 90 with substitution of Ala-Val (8/45, 17.8%). The remaining substitutions were Gly88Cys (1/45, 2.2%), Asp89Asn (1/45, 2.2%), Ser91Pro (1/45, 2.2%). Notably, substitution Ser95Thr in
gyrA known to be not associated with FQs resistance was found in all FQs resistance isolates. No nonsynonymous mutations were identified in the
gyrB gene (Table
3).
Table 3
Mutations conferring antibiotices resistance
gyrA | G262T | Gly88Cys | LFX | 1 |
MXF | 1 |
G265A | Asp89Asn | LFX | 1 |
MXF | 1 |
C269T | Ala90Val | LFX | 8 |
MXF | 6 |
T271C | Ser91Pro | LFX | 1 |
MXF | 1 |
G280T | Asp94Tyr | LFX | 11 |
MXF | 11 |
G280A | Asp94Asn | LFX | 4 |
MXF | 4 |
A281C | Asp94Ala | LFX | 6 |
MXF | 5 |
A281G | Asp94Gly | LFX | 13 |
MXF | 9 |
G284C | Ser95Thr | LFX | 44 |
MXF | 34 |
Rv0678 | A152G | Gln31Arg | BDQ | 1 |
CFZ | 1 |
T157C | Ser53Pro | BDQ | 1 |
CFZ | 1 |
rplC | T460C | Cys154Arg | LZD | 2 |
ddn | G241A | Gly81Ser | DMD | 2 |
fbiC | G952A | Val318Ile | DMD | 1 |
A total of 3 strains were identified as CFZ resistant, sequence analysis revealed that all these strains harbored no nucleotide substitution in the rv1979c gene. And no mutation was observed in atpE gene of BDQ resistant isolates. All two CFZ-BDQ cross resistant strains had a mutation in the Rv0678 gene, one with Gln31Arg substitution and the other with Ser53Pro.
Of the four isolates resistant to LZD, two isolates carried mutations in rplC gene with amino acid substitution of Cys154Arg, while 23S rRNA and rplD gene seemed not to confer LZD resistance among these strains.
In addition, five candidate genes associated with DLM resistance was also analyzed in four DLM-resistant isolates. No mutations were observed in fbiA, fbiB, and fgd1 genes, while one isolate with the mutations in codon 318 of fbiC gene and two isolates in codon 81 of ddn gene.
Discussion
Since the MDR-TB cases have emerged as a major obstacle to global TB control due to small number of effective drugs and high risk of adverse effects, promising candidates are needed to provide potential solutions to resolve this troublesome dilemma. Following a clinical study of novel regimens recommended for MDR-TB, we investigated drugs resistance from the groups A, B and C, and to analyze the genetic determinants of this resistance in MDR-TB isolates obtained from patients.
For the two newer FQs, our data revealed that 50.0% of MDR-TB strains were resistant to LFX, and 38.6% resistant to MFX in southwest of China. A study from mid-East of China showed that 37% of fluoroquinolone resistance events were in MDR
M. tuberculosis isolates [
10]. And a total of 76% LFX resistance and 73% MFX resistance MTB isolates were identified in a study from southern China [
11]. Another report from Shanghai revealed that among FQ-resistant
M. tuberculosis strains, 44% were multidrug-resistant isolates [
12]. The higher resistance rate of FQs in China may due to the overuse of FQs in the treatment of undiagnosed bacterial infections, highlights the urgent need to take action to fight FQs misuse in clinical practice. Molecular analysis showed that a total of 75.6% FQr isolates were shown to harbour mutations in
gyrA QRDR, with condon 94 being the most predominant mutation site, but no mutation in
gyrB gene was observed [
12]. The reported frequency in condon 94 is similar to that in Hong Kong (75%) [
13] and to that in Rwanda (75%) [
14], although it is lower than that in Russia (83%) [
15] and higher than that in Taiwan (50%) [
16], showing that mutations in
gyrA QRDR were the key factor leading to quinolone resistance in
M. tuberculosis in China.
As for BDQ and CFZ, more than 95% of MDR-TB strains were susceptible in this study. Though they are now being studied as a component of novel regimens for MDR-TB, mutations in the
Rv0678 gene, which causes the overexpression of efflux pump MmpS5-MmpL5, were found to result in cross-resistance between the two drugs [
17]. Consistent with previous studies, our data demonstrated that two of three CFZ-resistant isolates had
Rv0678 mutations and were cross-resistance to BDQ. However, no mutations in
Rv1979c were identified in CFZ-resistant isolates without
Rv0678 mutations. Further studies are needed to expand our understanding of mechanisms of resistance to CFZ by identifying additional mutations. Though several target-based resistance mutations in the
atpE gene have been described in BDQ-resistant strains, but no
atpE mutations were found in this study. Additional mechanisms may be contributed to the resistance of BDQ.
Linezolid was effectively used to treat of MDR strains [
6]. According to previous studies, the T460C mutation in
rplC gene was the most frequent among the LZD-resistant isolates [
18]. In this study, two MDR-TB isolates (2/4, 50%) were identified mutations in the
rplC gene, which was in line with previous studies. In addition, polymorphisms in any of five genes (
ddn, fgd1, fbiA, fbiB, and
fbiC) have been shown to lead to in vitro DLM resistance [
8].
Ddn gene, encoding an F
420-dependent mycobacterial nitroreductase, was associated with the prodrug activation. Resistance to DLM is caused by the loss of this ability to activate DLM [
19]. In a recent study by Liu et al. [
20], out of the ten primary resistant isolates, five were MDR-TB isolates with nonsynonymous mutation on
ddn. In this study, two MDR isolates with
ddn mutation conferring DLM resistance were identified. Besides, previous studies revealed that mutations in the coenzyme F
420 biosynthesis pathway result in the loss of
M. tuberculosis bacilli’s ability to activate PA-824, another nitroimidazole similar to DLM [
21]. So as a member of the coenzyme F
420 biosynthesis pathway,
FbiC was involved in DLM resistance. In this study, of the three DLM resistant isolates, one isolate with mutation in
fbiC gene, suggesting
fbiC serves as an important contributor to DLM resistance.
Conclusions
In conclusion, MDR-TB isolates exhibited a high proportion of resistance to FQs, whereas excellent activity against MDR-TB was observed in BDQ, LZD, DLM and CFZ in southwest of China. Strains with mutations in codon 94 of the gyrA gene are more likely to be associated with high-level FQs resistance. In addition, mutations in Rv0678 gene and rplC gene were related to clofazimine-bedaquiline cross resistance and linezolid resistance respectively, and mutations in fbiC and ddn gene may be conferred to delamanid resistance on M. tuberculosis isolates. And this study provides evidence for further application of new anti-TB drugs in the treatment of MDR-TB in China.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.